Alivus Life Sciences
Alivus Life Sciences Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Alivus Life Sciences Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Alivus Life Sciences Ltd trades at a P/E of 23.11× and P/B of 3.91×.
Valuation
Profitability
Growth
Financial Health
Alivus Life Sciences Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Alivus Life Sciences Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Alivus Life Sciences Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Alivus Life Sciences Ltd, switchable between annual and quarterly views, consolidated or standalone.
Alivus Life Sciences Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹13,169.61 Cr and reported EPS of ₹45.87.
Alivus Life Sciences segment analysis: revenue and profit mix.
Disclosed business segments at Alivus Life Sciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Alivus Life Sciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Alivus Life Sciences Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Alivus Life Sciences Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Alivus Life Sciences Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding (74.9%) indicates management confidence and stable ownership.
Virtually debt-free with a low 0.02 debt-to-equity ratio.
High Operating Profit Margin (OPM) of 26.34% reflects strong cost control.
Positive quarterly net profit trend, growing from 95.00 to 122.00.
Consistent EPS growth, with 9.11% over 5 years and 10.75% TTM.
What can break it.
Reported 0.00% for ROCE and ROE raises capital efficiency concerns.
Zero quarterly sales and profit variation indicates potential short-term stagnation.
Current stock price (908.00) significantly below 52-week high (1260.00).
High P/E ratio of 31.70 suggests a relatively elevated valuation.
Unsustainably high TTM payout ratio (281.50%) raises concerns about dividend sustainability.
What would change my mind.
Trim if P/E re-rates above 30. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 2.20. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 13%. The operating engine is no longer compounding capital efficiently.
Alivus Life Sciences Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Alivus Life Sciences Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Alivus Life Sciences Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Alivus Life Sciences Ltd — derived from the live tape, not yesterday's close.
Alivus Life Sciences Ltd last traded at ₹1,070.3 with an intraday range of ₹1,054.6–₹1,086 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1070.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1148.80 | +78.50 | +7.33% |
| R3 | 1117.40 | +47.10 | +4.40% |
| R2 | 1101.70 | +31.40 | +2.93% |
| R1 | 1086.00 | +15.70 | +1.47% |
| PIVOT | 1070.30 | 0.00 | 0.00% |
| CURRENT | 1070.30 | — | — |
| S1 | 991.80 | -78.50 | -7.33% |
| S2 | 1023.20 | -47.10 | -4.40% |
| S3 | 1038.90 | -31.40 | -2.93% |
| S4 | 1054.60 | -15.70 | -1.47% |
ALIVUS is trading Inside CPR, indicating Trading in the range
CPR is Narrower, suggesting likely for trending moves
Day's range: 1054.6 ~ 1066
Trading Above opening range, showing Bullishness
Alivus Life Sciences Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Alivus Life Sciences Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Alivus Life Sciences Ltd stood at 53.2% of traded volume, against a 20-day average of 51.8%.
Alivus Life Sciences announcements: results, concalls, ratings, M&A.
Filings Alivus Life Sciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Alivus Life Sciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 94 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Alivus Life Sciences Limited has informed the Exchange about Transcript of Earnings Call.
Analysts/Institutional Investor Meet/Con. Call Updates
Alivus Life Sciences Limited has informed the Exchange about Schedule of Investors/Analyst Meeting.
Analysts/Institutional Investor Meet/Con. Call Updates
Alivus Life Sciences Limited has informed the Exchange about Link of Earnings Call Recording
Analysts/Institutional Investor Meet/Con. Call Updates
Alivus Life Sciences Limited has informed the Exchange about Schedule of meet - Earnings Call.
General Updates
Alivus Life Sciences Limited has informed the Exchange about General Updates
Investor decks & rating reports.
Alivus Life Sciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Alivus Life Sciences has declared, sequenced by announce and record date.
Alivus Life Sciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Alivus Life Sciences Ltd: business, sector, key facts.
What Alivus Life Sciences Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Alivus Life Sciences Ltd operates in the Healthcare, listed as NSE: ALIVUS, BSE: 543322.
Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, is an Indian pharmaceutical company specializing in the development, manufacturing, and marketing of non-commoditized Active Pharmaceutical Ingredients (APIs). These APIs are crucial components used in the production of various finished dosage forms of medications.
The company's portfolio encompasses a wide range of APIs targeting diverse therapeutic areas. This includes cardiovascular disease treatments (like olmesartan, telmisartan, and perindopril), central nervous system disorder medications (zonisamide), diabetes treatments (sitagliptin), gastrointestinal drugs (solifenacin, mirabegron), oncology therapies, pain management drugs, and anti-infectives (atovaquone). Additionally, they offer adapalene (used in dermatology) and rosuvastatin (a cholesterol-lowering drug).
A significant aspect of Alivus's business model is the provision of contract development and manufacturing services (CDMO). This means they produce APIs not only for their own branded formulations but also for other multinational corporations and specialty pharmaceutical companies. This CDMO segment allows them to leverage their manufacturing expertise and capacity for a broader client base, contributing to revenue diversification.
Alivus boasts a global reach, exporting its APIs to major markets including Europe, North America, Latin America, Japan, and other international destinations. This broad geographical reach underscores the company’s success in establishing itself as a significant player in the global API market.
The company, a subsidiary of Nirma Limited, was incorporated in 2011 and is headquartered in Mumbai, India. Its recent name change to Alivus Life Sciences Limited, effective December 2024, reflects a potential strategic repositioning or branding effort within the pharmaceutical industry.
Questions investors ask about Alivus Life Sciences Ltd (ALIVUS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Alivus Life Sciences Ltd (ALIVUS)?
The current share price of Alivus Life Sciences Ltd (ALIVUS) is ₹1,070.3. Today, the stock has gained by ₹10.30 (0.97%), trading in a range of ₹1,054.6 to ₹1,086. The stock opened at ₹1,058 with a trading volume of 1,05,388 shares.
02Is Alivus Life Sciences Ltd stock a good investment for long-term?
Alivus Life Sciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹13,169.61 crores, P/E ratio of 23.11, ROE of 18.36%, and ROCE of 0.00%. The dividend yield stands at 0.48%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Alivus Life Sciences Ltd stock?
The 52-week high price of Alivus Life Sciences Ltd (ALIVUS) is ₹1,148.4, while the 52-week low is ₹819. Currently trading at ₹1,070.3, the stock is 76.3% away from its 52-week low and 6.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Alivus Life Sciences Ltd stock at the current price?
Whether to buy Alivus Life Sciences Ltd stock at ₹1,070.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 23.11 and P/B ratio of 3.91. Today's performance shows a gain of 0.97%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Alivus Life Sciences Ltd and when is the next dividend?
Alivus Life Sciences Ltd offers a dividend yield of 0.48%, which means for every ₹100 invested at the current price of ₹1,070.3, you can expect to receive approximately ₹0.48 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd's key financial metrics include: P/E Ratio: 23.11, P/B Ratio: 3.91, ROE: 18.36%, ROCE: 0.00%, Dividend Yield: 0.48%, EPS: ₹45.87, Book Value: ₹271.02, and Debt-to-Equity: 1.70. The company's market cap stands at ₹13,169.61 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Alivus Life Sciences Ltd stock performing today in the market?
Alivus Life Sciences Ltd stock opened at ₹1,058 and is currently trading at ₹1,070.3, showing a gain of ₹10.30 (0.97%). The intraday high is ₹1,086 and low is ₹1,054.6. The trading volume stands at 1,05,388 shares, indicating moderate market participation today.
08What is the P/E ratio of Alivus Life Sciences Ltd and what does it indicate?
Alivus Life Sciences Ltd has a Price-to-Earnings (P/E) ratio of 23.11, which means investors are willing to pay ₹23.11 for every ₹1 of earnings. With an EPS of ₹45.87, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Alivus Life Sciences Ltd (ALIVUS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy